AMY BIANCONE: Open Payments
NPI 1568452100 · CUMBERLAND, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$818 in 44 payments from 14 companies in 2025. Trend: 2023 $733 · 2024 $616 · 2025 $818
Food & beverage: $818
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $179 |
| Novo Nordisk Inc | 8 | $171 |
| ABBVIE INC. | 10 | $169 |
| Astellas Pharma US Inc | 3 | $54 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $53 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Boston Scientific Corporation | 1 | $20 |
| Abbott Laboratories | 1 | $20 |
Products named: UBRELVY, AIRSUPRA, Ozempic, VRAYLAR, BREZTRI, Rybelsus, Veozah, JARDIANCE.
Industry payments across MD — which companies pay providers there.
